Tokyo, July 10, 2006 (JCN) - Eli Lilly Japan announced o June 4 that it has obtained additional approval for Gemzar Injection (gemcitabine HC1), its proprietary anti-cancer agent, from the Ministry of Health, Labor and Welfare. The agent will now be available for the treatment of biliary tract cancer.
Initially approved in Japan in March 1999, Gemzar is currently indicated for the treatments of non-small cell lung cancer and pancreatic cancer.
The company expects that Gemzar, with its superior response rate and reduced side effects, will be an optimal choice for patients with biliary tract cancer.
